Although we have not yet determined the mechanism attributable for their expansion ex vivo, the presence of IFN-γ-producing CD3+CD4−CD8−γδ+ T cells has the potential to give overestimated T cell responses in large-scale vaccination trials involving influenza or other antigens when only effector CD4+ and CD8+ immune responses are required. The gene discussed is IFNG; the disease is influenza.